TOKYO -- Takara Bio will mass produce mRNA vaccines from next year on a contract basis, Nikkei has learned, becoming one of the first Japanese companies to build key manufacturing facilities that will help cut the nation's reliance on imports.
Takara Bio will repurpose equipment at its mainstay plant in Kusatsu, a city in Shiga Prefecture, with production starting as soon as January.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
